These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

788 related items for PubMed ID: 12370434

  • 1. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Oxenius A, Price DA, Günthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, García F, Hirschel B, McLean A, Phillips RE.
    Proc Natl Acad Sci U S A; 2002 Oct 15; 99(21):13747-52. PubMed ID: 12370434
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
    Palacios GC, Sanchez LM, Briones E, Ramirez TJ, Castillo H, Rivera LG, Vazquez CA, Rodriguez-Padilla C, Holodniy M.
    Int J Infect Dis; 2010 Jan 15; 14(1):e34-40. PubMed ID: 19467895
    [Abstract] [Full Text] [Related]

  • 4. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A, Delfraissy JF, Venet A, Meyer L, Sinet M, ANRS CO6 PRIMO Study Group.
    Antivir Ther; 2012 Jan 15; 17(6):1001-9. PubMed ID: 22865544
    [Abstract] [Full Text] [Related]

  • 5. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection.
    Streeck H, Jessen H, Alter G, Teigen N, Waring MT, Jessen A, Stahmer I, van Lunzen J, Lichterfeld M, Gao X, Allen TM, Carrington M, Walker BD, Rockstroh JK, Altfeld M.
    J Infect Dis; 2006 Sep 15; 194(6):734-9. PubMed ID: 16941338
    [Abstract] [Full Text] [Related]

  • 6. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.
    AIDS; 2008 Aug 20; 22(13):1583-8. PubMed ID: 18670217
    [Abstract] [Full Text] [Related]

  • 7. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection.
    Lacabaratz-Porret C, Urrutia A, Doisne JM, Goujard C, Deveau C, Dalod M, Meyer L, Rouzioux C, Delfraissy JF, Venet A, Sinet M.
    J Infect Dis; 2003 Mar 01; 187(5):748-57. PubMed ID: 12599048
    [Abstract] [Full Text] [Related]

  • 8. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B, Swiss HIV Cohort Study.
    Arch Intern Med; 2003 May 26; 163(10):1220-6. PubMed ID: 12767960
    [Abstract] [Full Text] [Related]

  • 9. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.
    Carcelain G, Tubiana R, Samri A, Calvez V, Delaugerre C, Agut H, Katlama C, Autran B.
    J Virol; 2001 Jan 26; 75(1):234-41. PubMed ID: 11119593
    [Abstract] [Full Text] [Related]

  • 10. Treatment interruptions in HIV-infected subjects.
    Bongiovanni M, Casana M, Tincati C, d'Arminio Monforte A.
    J Antimicrob Chemother; 2006 Sep 26; 58(3):502-5. PubMed ID: 16816398
    [Abstract] [Full Text] [Related]

  • 11. Role of hydroxyurea during structured treatment interruptions.
    Foli A, Seminari E, Ravot E, Lisziewicz J, Lori F.
    J Biol Regul Homeost Agents; 2002 Sep 26; 16(1):64-8. PubMed ID: 12003177
    [Abstract] [Full Text] [Related]

  • 12. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A, Martinez E, Milinkovic A, Mora B, Mallolas J, Blanco JL, Larrousse M, Laguno M, Gallart T, Plana M, Gatell JM, Garcia F.
    J Antimicrob Chemother; 2009 Jan 26; 63(1):184-8. PubMed ID: 19001447
    [Abstract] [Full Text] [Related]

  • 13. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
    López M, Soriano V, Rallón N, Cascajero A, González-Lahoz J, Benito JM.
    Eur J Immunol; 2008 Jun 26; 38(6):1548-58. PubMed ID: 18421792
    [Abstract] [Full Text] [Related]

  • 14. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K.
    Clin Infect Dis; 2005 Mar 01; 40(5):728-34. PubMed ID: 15714420
    [Abstract] [Full Text] [Related]

  • 15. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A, Cox AE, Shamji MH, John L, Nelson M, Henderson DC, Gotch FM, Gazzard BG, Kelleher P.
    Antivir Ther; 2007 Mar 01; 12(6):971-5. PubMed ID: 17926652
    [Abstract] [Full Text] [Related]

  • 16. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.
    Jacobson JM, Pat Bucy R, Spritzler J, Saag MS, Eron JJ, Coombs RW, Wang R, Fox L, Johnson VA, Cu-Uvin S, Cohn SE, Mildvan D, O'Neill D, Janik J, Purdue L, O'Connor DK, Vita CD, Frank I, National Institute of Allergy and Infectious Diseases-AIDS Clinical Trials Group 5068 Protocol Team.
    J Infect Dis; 2006 Sep 01; 194(5):623-32. PubMed ID: 16897661
    [Abstract] [Full Text] [Related]

  • 17. Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection.
    Montes de Oca Arjona M, Pérez Cano R, Orozco MJ, Martín Aspas A, Guerrero F, Fernández Gutiérrez Del Alamo C, Girón-González JA.
    Clin Microbiol Infect; 2005 Jan 01; 11(1):57-62. PubMed ID: 15649305
    [Abstract] [Full Text] [Related]

  • 18. [The current status of structured treatment interruption].
    Nakata H, Mitsuya H.
    Nihon Rinsho; 2002 Apr 01; 60(4):807-12. PubMed ID: 11968793
    [Abstract] [Full Text] [Related]

  • 19. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART.
    Maggiolo F, Airoldi M, Callegaro A, Martinelli C, Dolara A, Bini T, Gregis G, Quinzan G, Ripamonti D, Ravasio V, Suter F.
    AIDS; 2009 Apr 27; 23(7):799-807. PubMed ID: 19114869
    [Abstract] [Full Text] [Related]

  • 20. Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients.
    Keh CE, Shen JM, Hahn B, Hallahan CW, Rehm CA, Thaker V, Wynne SM, Davey RT, Lane HC, Sereti I.
    AIDS; 2006 Feb 14; 20(3):361-9. PubMed ID: 16439869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.